Physician profile
Saka Aramide Kazeem
NPI 1922057397
$28,349.76
in general payments reported to CMS, 2019-2025
47 companies · $7,687 in 2025
The $7,687 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,653 · 2020: $2,061 · 2021: $906 · 2022: $1,024 · 2023: $6,884 · 2024: $7,135 · 2025: $7,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $19K · Food and Beverage: $3,098 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $18,514.22 |
| Food and Beverage | $3,097.82 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cambridge Interventional LLC | $18,328.63 | 2023-2025 | Crf |
| Medtronic Minimed, INC. | $2,679.43 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $858.53 | 2021-2025 | |
| Amgen INC. | $662.88 | 2019-2025 | Tepezza, Prolia, Evenity |
| Esaote North America, INC. | $514.22 | 2025 | |
| Novo Nordisk INC | $493.78 | 2019-2025 | Ozempic |
| Xeris Pharmaceuticals, INC. | $453.96 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $433.72 | 2019-2023 | |
| Medtronic, INC. | $384.48 | 2021-2025 | Symplicity G3, Minimed 780g |
| Janssen Pharmaceuticals, INC | $373.16 | 2019-2022 | |
| Corcept Therapeutics | $285.95 | 2019-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $267.17 | 2021-2025 | Unithroid |
| Lilly USA, LLC | $187.40 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $157.32 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.09 | 2020-2023 | Jardiance |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $132.58 | 2021-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $130.74 | 2024-2025 | Cequr Simplicity |
| Chiesi USA, INC. | $119.12 | 2025 | Mycapssa |
| Mannkind Corporation | $114.14 | 2022-2023 | Afrezza |
| Phathom Pharmaceuticals, INC. | $114.09 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $113.67 | 2019-2025 | |
| Horizon Therapeutics Plc | $109.78 | 2022-2023 | Tepezza |
| Insulet Corporation | $102.32 | 2021-2023 | Omnipod |
| Merck Sharp & Dohme LLC | $95.65 | 2019-2021 | |
| Madrigal Pharmaceuticals | $92.68 | 2025 | Rezdiffra |
| Amryt Pharma Holdings Ltd | $83.60 | 2022-2023 | Mycapssa |
| Abbvie INC. | $82.96 | 2020-2025 | |
| Amarin Pharma, INC. | $80.04 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $76.79 | 2019-2020 | |
| Grt US Holding, INC. | $76.67 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $76.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.91 | 2019 | |
| Antares Pharma, INC. | $73.42 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Calliditas Therapeutics US INC. | $56.61 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $39.40 | 2021-2022 | |
| Radius Health, INC. | $32.39 | 2020 | |
| Exact Sciences Corporation | $32.14 | 2025 | The Cologuard Plus Collection Kit |
| Vistapharm, INC. | $30.68 | 2021 | |
| Ascendis Pharma Endocrinology INC | $29.05 | 2023-2025 | Yorvipath |
| Ionis Pharmaceuticals, INC. | $24.18 | 2025 | Tryngolza |
| Tandem Diabetes Care, INC. | $23.46 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $20.75 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Arbor Pharmaceuticals, INC. | $19.79 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.77 | 2022 | |
| Intuity Medical INC | $16.06 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Cormedix INC. | $14.88 | 2025 | Defencath |
| Clarus Therapeutics INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saka Kazeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.